IMGN Related Analyst Ratings
-
Jefferies Lifts Immunogen (IMGN) PT by $7 on Better Kadcyla Pricing
-
Oppenheimer Downgrades Immunogen Inc. (IMGN) to Perform
-
Guggenheim Starts Immunogen Inc. (IMGN) at Neutral
-
UPDATE: Immunogen Inc. (IMGN) Falls on New Sell Rating
-
Oppenheimer Maintains an 'Outperform' on Immunogen Inc. (IMGN); Advancing NORTH
-
Jefferies Maintains a 'Buy' on Immunogen Inc. (IMGN); EMILIA Becomes Statistically Significant
-
Stifel Nicolaus Starts Immunogen Inc. (IMGN) at Hold
-
Cowen Starts Immunogen Inc. (IMGN) at Outperform
-
Cantor Fitzgerald Starts Immunogen Inc. (IMGN) at Hold, $15 Target
-
Oppenheimer Says Immunogen (IMGN) Results from ASCO Confirms T-DM1's Strong Profile in mBC
-
Jefferies Maintains Bullish Stance On Immunogen (IMGN) Following Data
-
Roth Capital Starts Immunogen Inc. (IMGN) at Buy
-
Canaccord Genuity Reiterates a 'Buy' on Immunogen (IMGN); Strong 2012 Catalyst Lineup
-
Canaccord Genuity Reiterates a 'Buy' on Immunogen (IMGN); Raising PT
-
Jefferies Comments on Immunogen (IMGN) Following ESMO Meeting, Positive Feedback on T-DM1
-
Canaccord Genuity Maintains a 'Buy' on Immunogen (IMGN); Breakthrough P2 Results Support High T-DM1 Potential
-
Canaccord Genuity Maintains a 'Buy' on Immunogen (IMGN); 2012 A Pivotal Year
-
Jefferies Starts Immunogen Inc. (IMGN) at Buy
-
Morgan Joseph Reiterates a 'Buy' on Immunogen (IMGN); Encouraging Incremental Data From IMGN901 and SAR3419
-
William Blair Starts Immunogen Inc. (IMGN) at Outperform
-
Boenning & Scattergood Starts Immunogen Inc. (IMGN) at Neutral; Transforming Antibodies Into Magic Bullets, but Shares Appear Fully Valued
-
Canaccord Genuity on ImmunoGen (IMGN): Keeping Abreast of Things
-
RBC Capital Upgrades Immunogen Inc. (IMGN) to Outperform
-
Brean Murray Carret & Co. Raises Price Target on Immunogen (IMGN), Maintains Buy Rating
-
Needham & Company Maintains an 'Underperform' on Immunogen (IMGN); Near-Term Value Creation Lacking
-
Canaccord Genuity Morning Coffee on Immunogen (IMGN): Not So Much
-
Needham & Company Maintains an 'Underperform' on Immunogen (IMGN); Broad but Still Risky Plans for T-DM1 and Pipeline, Solid Cash Position, & Lack of 2011 Milestones
-
Needham & Company Maintains an 'Underperform' on Immunogen (IMGN); T-DM1 Data Encouraging, Awaiting Further Data Updates to Pivotal Trial
-
Canaccord Genuity on Life Sciences/Biotechnology: Selected Small Cap Biotech Roundup
-
Needham & Company Initiates Coverage on ImmunoGen (IMGN) with an Underperform
-
Morgan Joseph Reiterates a 'Buy' on ImmunoGen (IMGN); Deal Brings Unprecedented Financial Stability
-
J.P. Morgan Initiates Coverage on Biotechnology Stocks (LXRX & IMGN)
-
Cantor Fitzgerald Maintains an 'Buy' on ImmunoGen (IMGN); Lowers PT
-
RBC Capital Downgrades Immunogen (IMGN) to Sector Perform
-
Morgan Joseph Reiterates a 'Buy' on CCI, IMGN, ALVR & SBAC
-
Morgan Joseph Reiterates a 'Buy' on ImmunoGen (IMGN); T-DM1 Approval in 2011 Likely With Current Data
-
Canaccord Adams Maintains a 'Buy' on ImmunoGen (IMGN); T-DM1 Reg Strategy Expected
-
Brean Murray Reiterates a 'Buy' on ImmunoGen (IMGN); Beyond NDA Filing Is a Long List of Upcoming Value-Creating Events
-
Canaccord Initiates Coverage on ImmunoGen (IMGN) with a Buy
-
Brean Murray Starts ImmunoGen (IMGN) at Buy
-
Brean Murray Initiates Coverage on ImmunoGen (IMGN) with a Buy; Still Deeply Undervalued
-
Wedbush Morgan Reiterates a 'Buy' Rating on ImmunoGen (IMGN); Positive Surprise From License Agreement
-
Lazard Capital Downgrades ImmunoGen (IMGN) to Hold
-
Oppenheimer Initiates Coverage on ImmunoGen (IMGN) with an Outperform
-
Cantor Fitzgerald Maintains a 'Buy' on ImmunoGen (IMGN); Raises Price Target
-
Morgan Joseph Reiterates a 'Buy' on ImmunoGen (IMGN); Expect Larger T-DM1 Contribution
-
Morgan Joseph Initiates Immunogenic (IMGN) with a Buy
-
Summary Of Today's Upgrades And Downgrades
-
RBC Capital upgrades ImmunoGen (IMGN) to Outperform
-
Lazard Capital Markets Starts Immunogen (IMGN) with a Buy
Back to IMGN Stock Lookup
